002653 Stock Overview
Research, develops, manufactures, and sells pharmaceuticals in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Haisco Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥34.60 |
| 52 Week High | CN¥40.66 |
| 52 Week Low | CN¥18.59 |
| Beta | 0.074 |
| 1 Month Change | -4.42% |
| 3 Month Change | 5.94% |
| 1 Year Change | 64.14% |
| 3 Year Change | 71.80% |
| 5 Year Change | 71.12% |
| Change since IPO | 391.17% |
Recent News & Updates
Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?
Dec 19
Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon
Nov 19Recent updates
Is Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Trading At A 38% Discount?
Dec 19Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares May Have Run Too Fast Too Soon
Nov 19Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations
Aug 22With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For
Jul 25Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet
Jul 04Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)
Jun 17These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well
Mar 19Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)
Feb 27Shareholder Returns
| 002653 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.2% | -1.9% | -1.2% |
| 1Y | 64.1% | -1.8% | 11.8% |
Return vs Industry: 002653 exceeded the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 002653 exceeded the CN Market which returned 11.8% over the past year.
Price Volatility
| 002653 volatility | |
|---|---|
| 002653 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002653 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002653's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 5,448 | Xiu Lian Fan | www.haisco.com |
Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular.
Haisco Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 002653 fundamental statistics | |
|---|---|
| Market cap | CN¥38.38b |
| Earnings (TTM) | CN¥476.19m |
| Revenue (TTM) | CN¥3.72b |
80.6x
P/E Ratio10.3x
P/S RatioIs 002653 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002653 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.72b |
| Cost of Revenue | CN¥1.04b |
| Gross Profit | CN¥2.69b |
| Other Expenses | CN¥2.21b |
| Earnings | CN¥476.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.43 |
| Gross Margin | 72.17% |
| Net Profit Margin | 12.79% |
| Debt/Equity Ratio | 49.4% |
How did 002653 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield80%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 05:04 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Haisco Pharmaceutical Group Co., Ltd. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue Gao | Changjiang Securities Co. LTD. |
| Shanshan Li | China Merchants Securities Co. Ltd. |
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |